Drug intelligence / Profile preview

rVSV HIV envC

Development stage: Phase 1
Lead developer: Aurobindo Pharma
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

rVSV HIV envC is a recombinant vesicular stomatitis virus (rVSV) vector-based HIV vaccine candidate that expresses HIV-1 subtype C envelope (Env) protein. This vaccine is part of a prime-boost vaccination strategy, typically used after DNA vaccine priming. The vaccine is based on a highly attenuated, replication-competent rVSV platform, which has been modified to enhance safety while maintaining immunogenicity. It was developed specifically for regions where HIV-1 subtype C is the predominant circulating strain, such as sub-Saharan Africa.

Other names: rVSV-ZEBOV carrying CO A74 Env chimerasrVSV subtype C Env vaccine

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on rVSV HIV envC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rVSV HIV envC.

Explore the full profile